Sales of large varieties soared by 1300%, Qilu first imitated listing

The only domestic company that has a layout to imitate ceftazidime and Avibactam sodium for injection, Qilu Pharmaceutical may quickly occupy the market

01.

It is worth noting that only Qilu is currently deploying imitation of Ceftazidime Avibactam Sodium for injection, which is also the first imitation in China

Sunitinib malate capsules are deemed to have passed the consistency evaluation, and the 25 mg, 37.

The Insight database shows that ceftazidime avibactam sodium was developed by Pfizer and was first approved by the FDA in February 2015.

Ceftazidime Avibactam Sodium is a new enzyme inhibitor compound preparation, which is composed of the third-generation cephalosporin antibacterial drug Ceftazidime and the sodium salt of the new β-lactamase inhibitor Avibactam

The 2005-2018 monitoring results of the China Bacterial Resistance Surveillance Network showed that among clinical isolates, gram-positive bacteria accounted for about 30%, and the remaining 70% were gram-negative bacteria

According to a report by the World Health Organization, infectious diseases in China account for more than 50% of all diseases.

The launch of Qilu Pharmaceutical's ceftazidime and avibactam sodium for injection may inject new impetus into the treatment of drug-resistant bacteria in China

02.

According to the 2020 sample hospital data of China Pharmaceutical Industry Information Center, cephalosporins accounted for 44% of the systemic antibacterial drug market, followed by other lactams (14.

After SFT was approved for listing in China, the first-day prescriptions were quickly prescribed in many hospitals in Hangzhou and Shanghai

According to data from Meinenet, in 2020, the sales of terminal ceftazidime and avibactam sodium in public medical institutions in China will exceed 200 million yuan, a year-on-year increase of 1343.

At present, apart from Qilu Pharmaceutical, no other company has declared this drug for the market

Cyberlan's inquiry on Qilu Pharmaceutical's official WeChat account found that Qilu has deployed a number of antibacterial products, including cefepime hydrochloride for injection and cefprozil granules

03.
Opportunities and challenges coexist in the antibiotic market

Anti-infective drugs are basic drugs, and the market scale in our country should not be underestimated
.
According to statistics compiled by the Prospective Industry Research Institute, the market size of China's human antibiotic drugs in 2018 was 25.
6 billion U.
S.
dollars, and it will grow to 26.
5 billion U.
S.
dollars in 2019, an increase of 3.
52% year-on-year
.

In recent years, various national policies have been issued one after another, and the development of pharmaceutical companies in the antibiotic market is not a small challenge
.

This year, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance", requiring the standardization of drug treatment for infectious diseases caused by pathogenic microorganisms such as bacteria, mycoplasma, chlamydia, rickettsiae, spirochetes, and fungi
.

The document also clearly stated that the rational use of antimicrobial drugs should be included in the hospital review, public hospital performance assessment, and rational drug use assessment, and the requirements for the assessment weight should be appropriately increased
.

This is also widely believed by industry insiders that on the basis of the country's further strengthening of antimicrobial drug management, antibiotic drugs will gradually be strictly controlled, and the market may face challenges
.

Back in 2009, WHO called on countries to use antibiotics cautiously to prevent the generation of more resistant bacteria.
Since 2011, China has successively introduced many "resistance restriction" policies and measures
.

At the same time, antibiotic products also accounted for a larger share in volume purchases
.
The fifth batch of four cephalosporins collected by the country-cefazolin, cefuroxime, ceftriaxone, and ceftazidime, are all commonly used clinically antibiotic products
.
According to CCTV reports, the price of cephalosporin antibacterial drugs dropped by an average of 75% in the fifth batch of national procurement
.

In this context, many pharmaceutical companies have stepped up research and development of new drugs and accelerated their transformation and upgrading
.

Taking Guangzhou Pharmaceutical Group as an example, it gradually shifted to the four directions of chronic disease, anti-tumor medication, cardiovascular medication and anti-ED series medications after the "limitation of anti-inflammatory drugs".
Baiyunshan has developed a series of "star products" such as " "Huatuo Zaizao Pills", "Wuji Baifeng Pills" and so on
.

From the perspective of Qilu Pharmaceutical, in addition to deploying anti-infective drugs, R&D investment has also been increasing in recent years, even exceeding 10% of sales revenue
.

From the listing of the anti-infective drug Ceftazidime Avibactam Sodium, it can be seen that proactive attack has become the best way for pharmaceutical companies to occupy the market
.